Theodore Saad, MD
Nephrology · Newark, DENPI 1417943994
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 46.3% of the total. Among nephrology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $197.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$12K
- Calliditas Therapeutics US Inc.$4K
- W. L. Gore & Associates, Inc.$3K
- CSL Behring$3K
- Medtronic$1K
- Amgen$357
- plus $2K from 26 others
Across 133 payments — averaging $5051.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$192K
- Cook Research Incorporated$148K
- Merit Medical Systems Inc$94K
- Akebia Therapeutics Inc$73K
- Boehringer Ingelheim$58K
- Vertex$54K
- plus $52K from 5 others
What the payments were for
- Consulting fees$13,06551%
- Speaking & faculty fees$5,80023%
- Travel & lodging$2,49710%
- Food & beverage$3,97016%
- Education$1961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 18 | $11,828 |
| Calliditas Therapeutics US Inc. | 3 | $4,375 |
| W. L. Gore & Associates, Inc. | 7 | $3,167 |
| CSL Behring | 8 | $2,611 |
| Medtronic | 10 | $1,053 |
| Amgen(2 entities) | 13 | $357 |
| Merit Medical Systems Inc | 1 | $350 |
| AstraZeneca | 7 | $225 |
| Otsuka America Pharmaceutical, Inc. | 7 | $202 |
| Travere Therapeutics, Inc. | 4 | $165 |
| Fresenius USA Marketing, Inc. | 9 | $152 |
| Boston Scientific | 8 | $152 |
| Nxstage Medical, Inc. | 2 | $130 |
| Novartis | 3 | $129 |
| Mallinckrodt Hospital Products Inc. | 4 | $103 |
| Venturemed Group, Inc. | 1 | $85 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Boehringer Ingelheim | 3 | $55 |
| Inari Medical, Inc. | 2 | $45 |
| Vifor Pharma, Inc. | 2 | $44 |
| Bayer | 2 | $33 |
| Kyowa Kirin, Inc. | 1 | $29 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Gilead | 1 | $27 |
| Angiodynamics, Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| GSK | 1 | $15 |
| Sanofi | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $11 |
| Cook Medical LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TARPEYO$4,345
- GORE VIABAHN Endoprosthesis with Heparin$2,507
- GORE VIABAHN Endoprosthesis$2,340
- Product in Development$580
- ELLIPSYS VASCULAR ACCESS SYSTEM$570
- WRAPSODY Endovascular Stent Graft System$350
- COVERA$128
- IN.PACT Admiral$126
How this compares
$25,527 in reported general payments places this provider in the 95th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 12 | $9,250 |
| Potassium Chloride | 11 | $540 |
| Furosemide | 22 | $356 |
| Calcitriol | 15 | $299 |
| Losartan Potassium | 18 | $204 |
| Amlodipine Besylate | 17 | $190 |
| Hydralazine Hcl | 12 | $133 |
| Spironolactone | 12 | $128 |
| Prednisone | 41 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma | $225 | $9,25012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.